Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Lawrence Scott Blaszkowsky

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9437-2977; OpenAlex author ID A5081543892. Sources: ClinicalTrials.gov.

Their work

Papers
30 (first author 2, last author 0)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
0
Collaborators
104
Papers, trials and grants by year

2006: 2 trials · 2007: none · 2008: none · 2009: 1 trial · 2010: none · 2011: 1 paper · 2012: 2 papers · 2013: 4 papers · 2014: 3 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 3 papers · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: none · 2023: 5 papers · 2024: 1 paper · 2025: none · 2026: 3 papers

Papers 30

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-25-2052↗
  3. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  4. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
  5. Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-023-05796-5↗
  6. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  7. Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. Co-author DOI 10.1097/sla.0000000000005354↗
  8. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Co-author DOI 10.1097/xcs.0000000000000499↗
  9. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-022-12976-1↗
  10. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Co-author DOI 10.1007/s11307-020-01569-7↗
  11. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Co-author DOI 10.1038/s43018-021-00269-7↗
  12. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Co-author DOI 10.1016/j.pan.2020.03.011↗
  13. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001590↗
  14. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoad… Co-author DOI 10.1245/s10434-019-08084-2↗
  15. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗
  16. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000002600↗
  17. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical … Co-author DOI 10.1001/jamaoncol.2018.0329↗
  18. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000336↗
  19. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Ca… Co-author DOI 10.1097/coc.0000000000000349↗
  20. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0000000000000867↗
  21. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable … Co-author DOI 10.1016/j.ijrobp.2014.03.034↗
  22. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Co-author DOI 10.1016/j.prro.2013.07.006↗
  23. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2013.10.027↗
  24. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at… Co-author DOI 10.1002/cncr.28329↗
  25. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic canc… Co-author DOI 10.1093/annonc/mdt066↗
  26. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Co-author DOI 10.1097/sla.0b013e318263da2f↗
  27. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. First author DOI 10.1634/theoncologist.2012-0435↗
  28. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Co-author DOI 10.1002/cncr.26633↗
  29. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Co-author DOI 10.1007/s10637-011-9708-3↗
  30. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Co-author DOI 10.1016/j.ijrobp.2009.10.061↗

Trials 3

  1. Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas Principal investigator NCT00948688↗
  2. Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic … Principal investigator NCT00307723↗
  3. Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer Principal investigator NCT00366457↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Theodore Sunki Hong · 26 shared papers, 2011–2026 · strength 2.45
  2. Jennifer Yon-Li Wo · 21 shared papers, 2012–2026 · strength 1.91
  3. David P. Ryan · 23 shared papers, 2011–2026 · strength 1.82
  4. Keith D. Lillemoe · 18 shared papers, 2013–2026 · strength 1.70
  5. Cristina Rosa Ferrone · 19 shared papers, 2013–2024 · strength 1.64
  6. Motaz Qadan · 11 shared papers, 2019–2026 · strength 1.54
  7. Colin D. Weekes · 10 shared papers, 2019–2026 · strength 1.45
  8. Aparna R. Parikh · 8 shared papers, 2019–2026 · strength 1.11
  9. Carlos F. Fernandez-del Castillo · 15 shared papers, 2011–2023 · strength 1.04
  10. Carlos Fernández-del Castillo · 7 shared papers, 2013–2026 · strength 0.71
  11. Eunice Lee Kwak · 14 shared papers, 2011–2019 · strength 0.58
  12. David Tsai Ting · 5 shared papers, 2015–2026 · strength 0.57
  13. Priyadarshini Pathak · 3 shared papers, 2024–2026 · strength 0.57
  14. Hannah Johnson Roberts · 3 shared papers, 2024–2026 · strength 0.55
  15. Zhi Ven Fong · 3 shared papers, 2023–2024 · strength 0.50
  16. Andrew Louis Warshaw · 6 shared papers, 2013–2023 · strength 0.44
  17. Brian Matthew Wolpin · 5 shared papers, 2012–2026 · strength 0.40
  18. Thomas Adam Abrams · 4 shared papers, 2012–2026 · strength 0.37
  19. Fidel López‐Verdugo · 2 shared papers, 2023 · strength 0.33
  20. Janet E. Murphy · 6 shared papers, 2013–2019 · strength 0.33
  21. Florence K. Keane · 3 shared papers, 2018–2023 · strength 0.33
  22. Matthew B.B. Yurgelun · 2 shared papers, 2023–2026 · strength 0.31
  23. James M. Cleary · 2 shared papers, 2023–2026 · strength 0.31
  24. Jon Michael Harrison · 2 shared papers, 2020–2026 · strength 0.30
  25. Ryan David Nipp · 4 shared papers, 2018–2021 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.